Reverse Chemical Proteomics in Drug Discovery

M. GOTSBACHER; P. KARUSO

doi:10.3797/scipharm.oephg.21.SL-27

You are currently viewing a new version of our website. To view the old version click .

Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).

Abstract

16 April 2009

Reverse Chemical Proteomics in Drug Discovery

and

Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, NSW, 2109 Australia

Author to whom correspondence should be addressed.

Sci. Pharm.2009, 77(6), 194;https://doi.org/10.3797/scipharm.oephg.21.SL-27

Version Notes

Order Reprints

Abstract

With advances in separation technology and structure elucidation, the main bottleneck limiting drug development from natural products is the identification of their cellular targets. Although effective therapeutic agents can be developed and successfully administered without knowledge of the underlying mechanism of action, elucidation of drug target proteins is essential in the design of new compounds with improved safety and efficacy [1].[...]

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Falcarinol Content in Carrot Genotypes Determined by LC-MS

Absolute Bioavailability and Metabolism of Dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides (“tetraene”) after Intravenous and Oral Single Doses to Rats